Picture of Oncimmune Holdings logo

ONC Oncimmune Holdings Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-35.23%
3m-30.56%
6m-52.83%
1yr-64.47%
Volume Change (%)
10d/3m+38.76%
Price vs... (%)
52w High-68.92%
50d MA-30.16%
200d MA-48.6%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-397.5%
Return on Equity-760.96%
Operating Margin-222.49%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st May 202331st May 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Oncimmune Holdings EPS forecast chart

Profile Summary

Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer. The principal activity of the Company and its subsidiaries is that of autoantibodies profiling to the pharmaceutical and biotechnology industry, specifically in the areas of immune-oncology, autoimmune disease and infectious diseases, and the research, development and commercialization of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a range of solid tumor types. Its ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Its diagnostic products business is located at its laboratory facility in Nottingham, United Kingdom.

Directors

Last Annual
May 31st, 2022
Last Interim
May 31st, 2022
Incorporated
October 9th, 2015
Public Since
May 18th, 2016
No. of Employees
52
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
69,475,480

ONC Share Price Performance

Upcoming Events for ONC

Full Year 2022 Oncimmune Holdings PLC Earnings Release

Oncimmune Holdings PLC Annual Shareholders Meeting

Half Year 2023 Oncimmune Holdings PLC Earnings Release

Similar to ONC

Picture of Caretech Holdings logo

Caretech Holdings

gb flag iconLondon Stock Exchange

Picture of Chill Brands logo

Chill Brands

gb flag iconLondon Stock Exchange

Picture of CVS logo

CVS

gb flag iconLondon Stock Exchange

Picture of Integrated Diagnostics Holdings logo

Integrated Diagnostics Holdings

gb flag iconLondon Stock Exchange

Picture of IQ-AI logo

IQ-AI

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email